CDH2 and prostate cancer: N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype [15]; N-cadherin has been reported to be upregulated and associated with metastasis and poor prognosis in prostate cancer patients [16].